Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efeito da terapia de transferência elétrica capacitiva resistiva em feridas de difícil cicatrização

Efeito da terapia de transferência elétrica capacitiva resistiva na cicatrização de feridas e na expressão de biomarcadores em feridas de difícil cicatrização

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy (capacitive resistive electrical transfer therapy) has been shown to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote the regeneration of acute wounds and DHW (difficult-to-heal wounds).

Visão geral do estudo

Descrição detalhada

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy has been shown to be able to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote acute wound regeneration and CDH.

The working hypothesis is that CRET treatment promotes the healing of CDH through its action in regulating inflammatory and regenerative processes in skin tissue. This non-invasive, cost-effective treatment, devoid of identified adverse effects, and not studied in depth so far in patients with CDH, can thus be placed in the treatment algorithms of CDH with the correct selection of candidate patients.

Tipo de estudo

Intervencional

Inscrição (Estimado)

137

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Madrid
      • Madrid, Madrid, Espanha, 28034
        • Recrutamento
        • Hospital Ramón y Cajal
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 years of age or older

  • Agree to participate in the study and sign the informed consent form.

  • Inpatients or outpatients who can be followed by the research team for the duration of the study

  • Ulcers with a surface area of no less than 0.5 cm2 and of at least 4 weeks' duration (CDH), located on the lower limbs in the case of ulcers of venous etiology or on the foot, in the case of diabetic foot ulcers.

  • For patients with ulcers of venous etiology: ulcers of venous etiology stage 2, 3 4 with diagnosis of chronic venous insufficiency with open wound CEAP IVC C6 according to CEAP classification (38).

  • For patients with diabetic foot ulcers presenting:

    • Type 1 and type 2 diabetics with a glycated hemoglobin (HbA1c ≤10% (in a test no longer than 3 months).
    • Patients with UPD without PAD or with associated mild or moderate stage PAD (39) according to the criteria of the intersociety consensus for the treatment of peripheral arterial disease (TASC II).
    • UPD Grade 1A, 1C, 2A, 2C according to the Texas classification (40).
    • Patients who have required previous surgical debridement and 4 weeks have elapsed since such debridement.
  • Comorbidity is defined as the presence of at least one of the following criteria:

    • Smoking more than 10 cigarettes per day in the last 6 months.
    • Immunosuppression: systemic treatment with high-dose corticosteroids in the previous 3 months, severe active infection in the previous month, presence of systemic or organ-specific autoimmune disease.
    • Renal failure with creatinine > 2 mg/dl.
    • Respiratory failure with pO2< 90 mm Hg
    • Cardiac failure, grade II or higher
    • Anemia or nutritional deficit
    • Endocrine disruption under medical treatment
    • Neuropathy in the affected area or neurological disease.
    • Connective tissue diseases
    • Mobility impairment
    • Presence of microvascular disease

Exclusion Criteria:

  • Pregnancy
  • Patients with contraindications for CRET treatments (electronic implants, thrombophlebitis).
  • Patients with chronic or pathological wounds that required surgical intervention.
  • Ulcers with active infection according to IDSA classification in soft tissues or with clinical and/or radiological signs compatible with osteomyelitis.
  • Allergies to standard wound treatment.
  • Patients presenting severe renal insufficiency (Glomerular filtration rate ≤30 ml/min in analysis performed in the last 3 months).
  • Patient who has presented an acute ischemic event (acute myocardial infarction or stroke, in the 3 months prior to inclusion in the study).
  • Patients who present an evolving neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or immunosuppressants at the current moment.
  • Patients treated for a chronic condition requiring the intake of strong systemic corticosteroids doses ≥ 40 mg prednisone).
  • Critical non-revascularizable ischemia or TcPO2 < 25mmHg or a digital hallux systolic pressure < 50 mm Hg in diabetic foot ulcers.
  • Patients who do not accept to use the prescribed unloading treatment in the case of diabetic foot ulcers.
  • In the case of patients with ulcers of venous etiology, the presence of peripheral arterial disease in any of its stages.
  • Patients who do not accept the indicated compressive bandage treatment, in the case of ulcers of venous etiology.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: A-E group

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

Experimental: B-E group

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

Experimental: A-C grouop

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

Experimental: B-C grouop

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

Experimental: C-C group

Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.

standard clinical procedures

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Wound dimensions before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.
Prazo: 18 months

Wound dimensions measurement (area, length and width) before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.

18 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
General clinical evaluation:
Prazo: 18 months
  • age,
  • sex,
  • BMI
  • general medical history,
  • baseline blood work,
  • usual treatment
18 months
Wound evaluation:
Prazo: 18 months
  • cause,
  • location,
  • time of evolution,
  • photographs.
18 months
Evaluation of biomarkers in peripheral blood of patients with CDH with or without CRET treatment:
Prazo: 18 months

Quantification of cytokines and growth factors: IL-1α, IL-1β, TNFα, IFγ.

18 months
In primary cultures of fibroblasts isolated from biopsies of CDH patients with or without CRET treatment, assessment of typical CDH biomarkers related to:
Prazo: 18 months
  • Death: TUNEL assay; Bcl-2, Bcl-X and Caspase-3 markers.
  • Viability/proliferation: XTT, Ki67, p-p38 and p-ERK1/2 assays.
  • Adhesion: β -catenin and E-cadherin.
  • Extracellular matrix: α-SMA, Col I and Col III and the metalloproteinases, MMP8, MMP2 and MMP9.
18 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Maria Luisa Hernández Bule, PhD, IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de janeiro de 2024

Conclusão Primária (Real)

31 de julho de 2024

Conclusão do estudo (Estimado)

1 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

29 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de julho de 2023

Primeira postagem (Real)

20 de julho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CRET-ÚLCERAS-01

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever